Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 5.19 HKD -8.3% Market Closed
Market Cap: 4.2B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Ocumension Therapeutics
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ocumension Therapeutics
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Ocumension Therapeutics
HKEX:1477
Interest Income Expense
ÂĄ22.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Interest Income Expense
ÂĄ1.1B
CAGR 3-Years
52%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Interest Income Expense
ÂĄ149.9m
CAGR 3-Years
12%
CAGR 5-Years
5%
CAGR 10-Years
20%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Interest Income Expense
ÂĄ472.8m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Interest Income Expense
ÂĄ1.2B
CAGR 3-Years
-17%
CAGR 5-Years
-7%
CAGR 10-Years
37%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Interest Income Expense
-ÂĄ20.1m
CAGR 3-Years
-107%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
4.2B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Intrinsic Value
4.66 HKD
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Ocumension Therapeutics's Interest Income Expense?
Interest Income Expense
22.8m CNY

Based on the financial report for Dec 31, 2023, Ocumension Therapeutics's Interest Income Expense amounts to 22.8m CNY.

What is Ocumension Therapeutics's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-54%

Over the last year, the Interest Income Expense growth was -54%.

Back to Top